Ohnuma Kei, Ishii Tomonori, Iwata Satoshi, Hosono Osamu, Kawasaki Hiroshi, Uchiyama Masahiko, Tanaka Hirotoshi, Yamochi Tadanori, Dang Nam H, Morimoto Chikao
Division of Clinical Immunology, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.
Immunology. 2002 Nov;107(3):325-33. doi: 10.1046/j.1365-2567.2002.01510.x.
CD26 is T cell costimulatory molecule with dipeptidyl peptidase IV (DPPIV) enzyme activity located in its extracellular region. The expression of CD26 is enhanced after activation of T cells, while it is preferentially expressed on a subset of CD4+ memory T cells in the resting state. In this paper, we demonstrate that binding of the soluble anti-CD26 monoclonal antibody (mAb) 1F7 inhibits human T-cell growth and proliferation in both CD26-transfected Jurkat T-cell lines and human T-cell clones by inducing G1/S arrest, which is associated with enhancement of p21Cip1 expression. This effect depends on the DPPIV enzyme activity of the CD26 molecule. Moreover, we show that expression of p21Cip1 after treatment with the anti-CD26 mAb 1F7 appears to be induced through activation of extracellular signal-regulated kinase (ERK) pathway. These data thus suggest that anti-CD26 treatment may have potential use in the clinical setting involving activated T cell dysregulation, including autoimmune disorders and graft-vs.-host disease.
CD26是一种T细胞共刺激分子,在其细胞外区域具有二肽基肽酶IV(DPPIV)酶活性。T细胞激活后CD26的表达增强,而在静息状态下它优先表达于一部分CD4+记忆T细胞上。在本文中,我们证明可溶性抗CD26单克隆抗体(mAb)1F7通过诱导G1/S期阻滞,抑制CD26转染的Jurkat T细胞系和人T细胞克隆中的人T细胞生长和增殖,这与p21Cip1表达增强有关。这种效应取决于CD26分子的DPPIV酶活性。此外,我们表明用抗CD26 mAb 1F7处理后p21Cip1的表达似乎是通过细胞外信号调节激酶(ERK)途径的激活诱导的。因此,这些数据表明抗CD26治疗在涉及活化T细胞失调的临床环境中可能具有潜在用途,包括自身免疫性疾病和移植物抗宿主病。